Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Bernie Sanders calls for RFK Jr. to resign...
Top Senate Republican ready to go nuclear, ‘roll...
Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant...
Altech – CERENERGY Battery 46.7M Euro German Grant...
Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy
Heliostar Presents Second Quarter 2025 Financial Results
Apollo to Proceed with 5-for-1 Share Consolidation
Rhode Island’s ‘Taylor Swift Tax’ on vacation homes...
Former FBI Director Robert Mueller has Parkinson’s disease:...
Earthwise Advertising & Investor Awareness Campaign
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Senate confirms Dr Marty Makary as Trump’s FDA chief

by admin March 26, 2025
March 26, 2025
Senate confirms Dr Marty Makary as Trump’s FDA chief

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday.

His confirmation was cemented just hours after he cleared one last procedural test vote earlier in the evening. 

The Senate voted 56-44 to invoke cloture on the nomination prior to his final confirmation.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he will now lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

previous post
With Trump’s blessing, Israel has Hamas terrorists on back foot: ‘Operating in survival mode’
next post
Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

You may also like

Abbott signs Texas redistricting map into law, securing...

August 30, 2025

‘Flooding the zone’: Trump hits warp speed in...

January 25, 2025

Voice of America restored by judge after Trump...

April 23, 2025

GOP veteran-lawmakers drop scathing ‘stolen valor’ letter to...

August 22, 2024

DeSantis not keen on Musk’s new political party,...

July 8, 2025

Trump goes after Zelenskyy over ‘land swapping’ dispute,...

August 12, 2025

Unearthed emails reveal White House nixed Biden visiting...

August 12, 2025

Bernie Sanders to force Senate vote on blocking...

July 31, 2025

Biden cover-up probe heats up as another ex-White...

July 11, 2025

White House can’t say what assassination of top...

August 1, 2024

Recent Posts

  • Bernie Sanders calls for RFK Jr. to resign as HHS secretary over vaccine policies: ‘Rally the American people’
  • Top Senate Republican ready to go nuclear, ‘roll over’ Democrats with rule change to confirm Trump nominees
  • Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant Approval
  • Altech – CERENERGY Battery 46.7M Euro German Grant Approval
  • Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (903)
    • Investing (2,877)
    • Politics (3,527)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.